<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750148</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00126</org_study_id>
    <nct_id>NCT04750148</nct_id>
  </id_info>
  <brief_title>Validation of the Two-minute Walk Test in an Oncology Setting</brief_title>
  <acronym>2MWTOnco</acronym>
  <official_title>Assessment of Physical Ability in Oncology: a Validation Study of the Two-minute Walk Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aline Reinmann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>School of Health Sciences Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the validity of the 2-minute walk test (2MWT) compared to&#xD;
      the 6-minute walk test (TM6) for subjects with onco-hematological disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer and its treatments have an impact on the body as a whole. The analysis of the&#xD;
      subject's physical capacity is essential to know the basic level of the subject&#xD;
      pre-treatment, to evaluate progress following rehabilitation, to set goals to prevent decline&#xD;
      in physical capacity or to evaluate changes in physical capacity at different stages of&#xD;
      survival. The 6-minute walk test (6MWT) is frequently used in the clinic to assess the&#xD;
      physical capacity of the subject in oncology. A variant of the 6MWT exists and has been&#xD;
      little studied in an oncological context: the 2-minute walk test (2MWT). The 2MWT is&#xD;
      performed in the same way as the 6MWT: the same instructions and the same test procedure. It&#xD;
      offers the advantage of being less tiring for the test subjects and saves clinicians time.&#xD;
      The 2MWT has been validated in the past for people with COPD or after cardiac surgery. To our&#xD;
      knowledge, it has not been validated for cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: criterion validity with 6MWT</measure>
    <time_frame>One year and through study completion</time_frame>
    <description>Criterion validity will be assessed by calculating the strength of the correlation between 2MWT and 6MWT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint: convergent construct validity</measure>
    <time_frame>One year and through study completion</time_frame>
    <description>Convergent construct validity will be evaluated by calculating the strength of the correlation between the 2MWT and the 10m walk test at spontaneous/fast speed as well as with the unipodal equilibrium test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint: criterion validity between 10m walk test and 10m walk test self-tested</measure>
    <time_frame>One year and through study completion</time_frame>
    <description>Criterion validity will be assessed by calculating the strength of the correlation between the 10m walk test self-tested and the 10m walk test timed by the examiner.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer</arm_group_label>
    <description>Individuals with an oncology disease will be included in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6-minute walk test</intervention_name>
    <description>The subject walks as far as possible for 6 minutes along a 30m long corridor.</description>
    <arm_group_label>Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2-minutes walk test</intervention_name>
    <description>The subject walks as far as possible for 2 minutes along a 30m long corridor.</description>
    <arm_group_label>Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>10-meters walk test</intervention_name>
    <description>The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).</description>
    <arm_group_label>Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>One leg stance test</intervention_name>
    <description>The time held in unipodal equilibrium is measured by the examiner.</description>
    <arm_group_label>Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of 50 adults consulting at the University Hospitals for&#xD;
        their oncological disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have an onco-hematologic disease&#xD;
&#xD;
          -  Have medical authorization from the patient's oncologist authorizing gait tests&#xD;
&#xD;
          -  Participate in the HUG rehabilitation program&#xD;
&#xD;
          -  Be able to give consent by signature&#xD;
&#xD;
          -  To be of legal age&#xD;
&#xD;
          -  Do not present pain when walking more than 2/10&#xD;
&#xD;
          -  Be able to walk with or without technical aids for a period of 6 minutes (as per&#xD;
             patient's statement)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suffer from heart problems&#xD;
&#xD;
          -  Bone metastases at risk of fracture&#xD;
&#xD;
          -  Osteoporosis at high risk of fracture&#xD;
&#xD;
          -  Unbalanced Hypertension (hypertension)&#xD;
&#xD;
          -  Not being able to carry out the walk tests in their entirety&#xD;
&#xD;
          -  Not being able to perform the gait tests for reasons related to the side effects of&#xD;
             the treatments (anemia, undernutrition, vomiting, severe fatigue, risk of&#xD;
             thrombocytopenia, pain).&#xD;
&#xD;
          -  Not being able to carry out the walking test because of a lack of understanding of the&#xD;
             instructions or because of psychological problems.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline Reinmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Health Sciences Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bohannon RW, Bubela D, Magasi S, McCreath H, Wang YC, Reuben D, Rymer WZ, Gershon R. Comparison of walking performance over the first 2 minutes and the full 6 minutes of the Six-Minute Walk Test. BMC Res Notes. 2014 Apr 25;7:269. doi: 10.1186/1756-0500-7-269.</citation>
    <PMID>24767634</PMID>
  </reference>
  <reference>
    <citation>Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982 May 29;284(6329):1607-8.</citation>
    <PMID>6805625</PMID>
  </reference>
  <reference>
    <citation>Chan WLS, Pin TW. Reliability, validity and minimal detectable change of 2-minute walk test, 6-minute walk test and 10-meter walk test in frail older adults with dementia. Exp Gerontol. 2019 Jan;115:9-18. doi: 10.1016/j.exger.2018.11.001. Epub 2018 Nov 10.</citation>
    <PMID>30423359</PMID>
  </reference>
  <reference>
    <citation>Eden MM, Tompkins J, Verheijde JL. Reliability and a correlational analysis of the 6MWT, ten-meter walk test, thirty second sit to stand, and the linear analog scale of function in patients with head and neck cancer. Physiother Theory Pract. 2018 Mar;34(3):202-211. doi: 10.1080/09593985.2017.1390803. Epub 2017 Oct 25.</citation>
    <PMID>29068767</PMID>
  </reference>
  <reference>
    <citation>Gijbels D, Eijnde BO, Feys P. Comparison of the 2- and 6-minute walk test in multiple sclerosis. Mult Scler. 2011 Oct;17(10):1269-72. doi: 10.1177/1352458511408475. Epub 2011 Jun 3.</citation>
    <PMID>21642370</PMID>
  </reference>
  <reference>
    <citation>Kosak M, Smith T. Comparison of the 2-, 6-, and 12-minute walk tests in patients with stroke. J Rehabil Res Dev. 2005 Jan-Feb;42(1):103-7.</citation>
    <PMID>15742254</PMID>
  </reference>
  <reference>
    <citation>Leung AS, Chan KK, Sykes K, Chan KS. Reliability, validity, and responsiveness of a 2-min walk test to assess exercise capacity of COPD patients. Chest. 2006 Jul;130(1):119-25.</citation>
    <PMID>16840391</PMID>
  </reference>
  <reference>
    <citation>Reid L, Thomson P, Besemann M, Dudek N. Going places: Does the two-minute walk test predict the six-minute walk test in lower extremity amputees? J Rehabil Med. 2015 Mar;47(3):256-61. doi: 10.2340/16501977-1916.</citation>
    <PMID>25588644</PMID>
  </reference>
  <reference>
    <citation>Scalzitti DA, Harwood KJ, Maring JR, Leach SJ, Ruckert EA, Costello E. Validation of the 2-Minute Walk Test with the 6-Minute Walk Test and Other Functional Measures in Persons with Multiple Sclerosis. Int J MS Care. 2018 Jul-Aug;20(4):158-163. doi: 10.7224/1537-2073.2017-046.</citation>
    <PMID>30150899</PMID>
  </reference>
  <reference>
    <citation>Schmidt K, Vogt L, Thiel C, JÃ¤ger E, Banzer W. Validity of the six-minute walk test in cancer patients. Int J Sports Med. 2013 Jul;34(7):631-6. doi: 10.1055/s-0032-1323746. Epub 2013 Feb 26.</citation>
    <PMID>23444095</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>School of Health Sciences Geneva</investigator_affiliation>
    <investigator_full_name>Aline Reinmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>6-minute walk test</keyword>
  <keyword>2-minute walk test</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes will be made available.</ipd_description>
    <ipd_time_frame>Data will be available within 6 months of study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

